ALC Alcon AG

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available on Alcon's investor relations website, allowing broad access to the presentation. Alcon, a global leader in eye care for over 75 years, provides a broad portfolio of products to enhance sight and improve lives, serving more than 260 million people annually across 140+ countries.

Alcon Inc. stock is exhibiting a "quiet climb," with sustained multi-month uptrends and positive analyst sentiment, leading investors to question if the market fully appreciates its long-term potential. The company's focus on surgical innovation, premium products, and digitally assisted surgery, combined with robust procedure volumes, underpins its strong performance. While not a "meteoric return," Alcon presents consistent growth and resilience, rewarding patient capital.

Broadwood Partners, a significant shareholder in STAAR Surgical Company (STAA), has criticized the fourth postponement of the Special Meeting of Shareholders concerning STAAR's proposed acquisition by Alcon Inc. (ALC). Broadwood, owning 30.2% of STAAR's common stock, is urging shareholders to vote "AGAINST" the transaction, which has been reset for January 6, 2026, arguing that the deal is "ill-conceived" and the price is unsatisfactory. They believe the board cannot indefinitely avoid shareholder sentiment despite multiple efforts to garner support for the acquisition.

STAAR Surgical (NASDAQ: STAA) has adjourned its Special Meeting of Stockholders concerning the proposed merger with Alcon (SIX/NYSE: ALC) at Alcon's request. Originally scheduled for December 19, 2025, the meeting will now take place on January 6, 2026, at 8:30 a.m. Eastern Time. The record date for eligible stockholders remains October 24, 2025.

Alcon has utilized its right to mandate STAAR Surgical delay its special stockholder meeting, originally scheduled for December 19th, to January 6th. This decision comes amidst ongoing discussions and recommendations regarding STAAR Surgical's proposed sale to Alcon. Various stakeholders, including Defender Capital and Broadwood Partners, have expressed differing opinions on the merger, while Institutional Shareholder Services (ISS) has advised STAAR shareholders to vote in favor of the Alcon takeover bid.

Broadwood Partners, holding 30.2% of STAAR Surgical, criticizes the company's fourth postponement of the Special Meeting concerning its proposed acquisition by Alcon. Broadwood urges shareholders to vote "AGAINST" the transaction, arguing that the delays highlight the deal's deeply flawed nature and that further extensions will not fix its fundamental defects. They call on the Board and Alcon to accept the shareholder outcome with humility.